Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

National Cancer Institute (NCI)

Status and phase

Terminated

Phase 2

Conditions

Stage II Malignant Testicular Germ Cell Tumor

Stage III Malignant Testicular Germ Cell Tumor

Testicular Seminoma

Recurrent Ovarian Germ Cell Tumor

Recurrent Malignant Testicular Germ Cell Tumor

Stage III Ovarian Germ Cell Tumor

Stage II Ovarian Germ Cell Tumor

Ovarian Dysgerminoma

Treatments

Drug: imatinib mesylate

Other: laboratory biomarker analysis

Procedure: therapeutic conventional surgery

Study type

Interventional

Funder types

NIH

Identifiers

NCT00042952

CDR0000069487 (Registry Identifier)

CLB-90105

U10CA031946 (U.S. NIH Grant/Contract)

NCI-2012-02481

Details and patient eligibility

About

Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have progressive, refractory, or recurrent stage II or stage III testicular cancer or stage II or stage III ovarian cancer following cisplatin-based chemotherapy

Full description

OBJECTIVES:

I. Determine the activity of imatinib mesylate in patients with progressive, refractory, or recurrent pure testicular seminoma or ovarian germ cell dysgerminoma after cisplatin-based chemotherapy.

II. Determine the toxicity of this drug in this patient population. III. Determine KIT expression and identify mutations in the c-kit gene in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral imatinib mesylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial response or stable disease with normalization of human chorionic gonadotropin may undergo surgical resection of residual lesions at each tumor status assessment. If residual viable germ cell tumor is present in the resected specimen, patients may resume imatinib mesylate. If no viable germ cell tumor is present in the resected specimen, then no further therapy is administered.

Patients are followed every 3 months for 1 year and then every 6 months for 1 year.

PROJECTED ACCRUAL: A total of 32 patients will be accrued for this study within 32-38 months.

Enrollment

32 patients

Sex

All

Ages

15+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Histologically confirmed pure testicular seminoma or ovarian germ cell dysgerminoma
- Histologic documentation of metastatic/recurrent disease not required
Alpha-fetoprotein level must be normal, unless abnormal level is explained by other conditions and approved by the study chair
Clinical stage II or III
Progressive, refractory, or recurrent disease, meeting at least 1 of the following criteria:
- Measurable progressive disease
- Biopsy-proven residual disease
- Persistently elevated or rising B-human chorionic gonadotropin (HCG) titers, defined as at least 2 values above the upper limit of normal (ULN)
Cisplatin-refractory disease without option of potentially curative therapy, meeting 1 of the following criteria:
- Failed high-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) or autologous bone marrow transplantation (AuBMT)
- Ineligible for or refused PBSCT or AuBMT
- Unlikely to achieve long-term benefit from PBSCT or AuBMT
Current evidence of metastatic disease
- Unidimensionally measurable target lesions
  - At least 20 mm by conventional techniques (e.g., physical examination for clinically palpable lymph nodes and superficial skin lesions or chest x-ray for clearly defined lung lesions surrounded by aerated lung)
  - At least 10 mm by spiral CT scan or MRI
  - If measurable disease is confined to a solitary lesion, then its neoplastic nature must be confirmed by histology
  - Ultrasound may not be used to measure tumor lesions that are not easily accessible clinically
Non-measurable/non-target lesions, with HCG at least ULN, including the following:
- Bone lesions
- Pleural or pericardial effusions
- Ascites
- CNS lesions
- Leptomeningeal disease
- Irradiated lesions, unless progression documented after radiotherapy
Performance status - ECOG 0-2
Granulocyte count at least 1,500/mm^3
Platelet count at least 100,000/mm^3
Hemoglobin at least 9 g/dL (transfusion allowed)
Bilirubin no greater than 1.5 times upper limit of normal (ULN)
SGOT/SGPT no greater than 2.5 times ULN
Creatinine no greater than 1.5 times ULN
No other severe and/or uncontrolled concurrent medical illness
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective barrier contraception during and for 3 months after study participation
See Disease Characteristics
See Disease Characteristics
At least 4 weeks since prior chemotherapy
No concurrent chemotherapy
No concurrent hormonal therapy except steroids for adrenal failure, hormones for non-disease-related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic
See Disease Characteristics
At least 4 weeks since prior radiotherapy
Prior radiotherapy to a symptomatic lesion or one that may produce disability (e.g., unstable femur) allowed
No concurrent palliative radiotherapy
No concurrent grapefruit juice
No concurrent warfarin for therapeutic anticoagulation (concurrent mini-dose warfarin [1 mg orally per day] as prophylaxis allowed)